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1. INTRODUCTION 
Medicinal chemistry is interdisciplinary subject involving organic chemistry, 
Inorganic chemistry, Biochemistry, Physiology, Microbiology, Biology, Toxicology and 
Computer modeling in the research for better and new drug discovery. 
Generally medicinal chemistry is used to make new compound, determine its 
biological efficacy and alter the structure of the compound for optimum effect. 
Early drug design started with elucidation of structure in natural products followed by 
selective changes in the molecule. The later was done for many reasons, including the 
reduction of any undesirable side effect & to obtain better pharmacokinetic response. 
Modern drug design deals with the synthesis of new structure or by making changes 
in the existing compound and see what happen. This is a fairly recent discipline which is still 
in its infancy. 
The techniques of molecular graphics and computational chemistry have provided 
novel chemical structure that have led to new drugs with potent medicinal activates.  
 Medicinal chemistry covers the following stages:     
 i) In the first stage new active substance or drugs are identified and prepared from 
natural sources, organic chemical reaction. They are known as lead molecules.  
 ii) The second stage is optimization of lead molecule to improved potency, selectivity 
and to reduced toxicity.         
 Iii) The next stage involves the optimization of synthetic route for bulk production 
and modification of pharmacokinetic and pharmaceutical properties of active substance to 
perform it clinically useful.         
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 A. PYRIMIDINE3,50 
 Pyrimidine is an important heterocyclic molecule is associated with several biological 
activities. Pyrimidines are heterocyclic compound that have an atom of nitrogen at 
1’st and 3’nd position. 
                                                  
 Pyrimidine is the most important among the three isomeric diazines. 
                                              i)o-diazine 
                                              ii)m-diazine 
                                              iii)p-diazine 
                      
 Pyrimidine is the useful intermediate for the development of many chemotherapeutic 
agents. It is one of the main pyrimidine nucleuses in anticancer and antiviral agent. 
 Various potent drugs in market contains pyrimidine nucleus like pyrantel pamoate 
(anthelmintic), flucytosine (antifungal), minoxdil (antihypertension), fluorouracil and 
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floxuridine (antineoplastic), pyrimethamine (antimalarial), idoxuridine and 
trifluridine (antiviral). 
 The important pyrimidine compounds have diverse applications as bactericidal, 
fungicidal, analgesic, anti inflammatory, anticancer, antiviral, antimalarial, 
anthelmintic, antihypertension etc. 
 Pyrimidine ring is also found in vitamin and barbituric acid. 
 
 LEUCKART REACTION3 
 This reaction is reductive amination process which converts primary or secondary 
amine to tertiary amine using protonated ketone and formic acid. This reaction avoids 
the problem of quterization. 
 














 Amine reacts with protonated ketone to give iminium ion. 
 The iminium ion then react with formic acid to give methylated 
ammonium ion and release CO2 gas, where formic acid act as a reducing 
agent or hydride transfer reagent. 
 This CO2 gas leads the synthesis process to the next level of synthesis. 
 In this stage ammonium ion gets deprotonated to form final methylated 
amine product. 
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 If reaction occurs with primary amine same process follows twice to reach 
the tertiary amine   as a final product. 
                                                                           
    
                                          B. ANTIOXIDANT54     
 Anti-oxidant is a molecule that inhibits the oxidation of other molecules. Oxidation is 
a chemical reaction that transfers electrons or hydrogen from a substance to an oxidizing 
agent.           
Oxidation reaction can produce free radicals. In turn, these radicals can start chain 
reaction. When the reaction occurs in a cell, it can cause damage or death to the cell. Anti-
oxidants terminate this chain reaction by remove free radical intermediates, and inhibit other 
oxidation reaction. So anti-oxidants are often reducing agents such as thiols, ascorbic acid or 
poly phenols. Ascorbic acid and tocopherols are antioxidant.    
 Antoxidant has been reduced risk factor such as aging, cancer, inflammatory disease, 
diabetes, heart diseases.         
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C. ANTICANCER DRUGS1 
Cancer is defined as a group of diseases which are characterized by uncontrolled cell 
proliferation and subsequent growth of abnormal tissue leading to profound changes in 
physiological function. Cancers can arise from both genetic and lifestyle factors that lead to 
abnormal regulation in the growth of particular stem cell populations. Anticancer or 
antineoplastic agents are the drugs used in the treatment of cancer, malignancy, tumour, 
carcinoma, sarcoma, leukemia etc.        
 Two key aspects of cellular life are i) DNA synthesis and mitosis to produce new cell 
and ii) cell differentiation which produces specialized cells.     
 Normal cell have control mechanisms to modulate these two processes by growth 
factor or growth inhibitor. A balance between cell growth and cell death is maintained, cell 
death is actively regulated by process known as “apoptosis”. Apoptosis is defined as a 
process of cell shrinkage, membrane blabbing and nuclear condensation.   
 Cancer cell, this regulatory process is aberrant; they produce over production of 
growth factor and avoid apoptosis which continue to multiply in an unregulated manner. The 
unregulated growth causes damage to DNA, resulting in mutations to genes that encode from 
protein controlling cell division.        
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D. ANTMICROBIAL DRUGS6 
The control of microorganism is essential for the prevention and treatment of 
diseases, microorganism also grow on and with in other organism, and how ever the 
microbial colonization can lead to disease, disability and even death. Thus the Control or 
destruction of micro organisms inside the human beings or other animals is great of 
importance. 
The Different chemical substances excreted by some micro organism, which inhibit 
the growth and development of other microbes it is called as antibiotics. Some of these drugs 
that are obtained naturally were put to chemical modifications in an attempt to enhance the 
beneficial effects mean while minimizing the toxic effects. 
The resultant modified product is termed as semi synthetic antibiotics, most of the 
antibiotics currently used are semi synthetic The chemists have synthesized many drugs that 
have got the antibacterial property and less toxicity, these drugs are called synthetic antibiotic 
drugs and it is further divided into, 
                        1. Anti bacterial drugs. 
                        2. Anti viral drugs. 
                        3. Antifungal drugs. 
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E. SYNTHESIS OF PYRIMIDINE AND ITS DERIVATIVE3 
 Gabrial synthesis: Pyrimidine is prepared from barbituric acid which in turn can 




 Whittaker syntheis: Pyrimidine is prepared by catalytic reductive dechlorination 
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 Todd synthesis:  4, 5, 6 triaminopyrimidine is prepared by the condensation of 
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 Pyrimidine derivative is prepared by condenasation of urea and malonic ester in the 




 2, 4-diamino 6-hydroxypyrimidine is obtained from ethyl cyanoacetate and guanidine 
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2. LITERATURE REVIEW 
 PADMASHRI et al., reported the synthesis of 2-(2’, 5’-substituted indole-3’-yl 
methylene imino)-4, 6–diaryl pyrimidine with a review to screen them for their 
antimicrobial activity (2002). 











 MISHRA et al., synthesized various derivatives of pyrimidine and evaluated their 
fungicidal activity (2004). 













 CJ SHISHOO et al., have prepared some substituted 6- phenyl and 7-phenyl thieno 
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 B.MURUGESH et al., have prepared some pyrimidine derivatives and evaluated for 
analgesic and anti- inflammatory activity (2007). 






 M.DAKSHELA et al., has synthesized and tested for pyrimidine derivatives with  
anticancer activity (1995). 
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AMIR et al.,have prepared some pyrimidine derivatives with hyperthyroidism activity. 
Thiouracil and its alkyl analogue, thio -barbital are efficient drug against hyperthyroidism 
(2001). 












 LEE et al., has synthesized some novel pyrimidine derivative having thiozolidinone. 
These compounds were evaluated for their glucose and lipid lowering activity (2005). 
 An efficient and reliable synthesis of pyrimidine derivatives with anthelmintic activity 
(1990). 





 T.EUNICE et al., has synthesized pyrimidine derivatives and evaluated for agents 
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 E.NIRANJI et al., Novel pyrimidines were synthesized by the condensation of 
chalcones of 4’-piperazine acetophenone with guanidine hydro chloride and evaluated 
for antihistamine activity (2000). 







 PALWINDER SINGH et al., have reacted 5-benzoyl/5-carbaldehyde/5-(3-phenyl 
acryloyl)-6-hydroxy -1H-pyrimidine-2 diones with amine provided the corresponding 
enamines with anticancer activity (1995). 










 STEPHANEPEDE BOSCQ et al., has synthesized 4-(2-methylanilino) benzothieno 
(2, 3-d) pyrimidine and 4-(2- methoxyanilino) benzothieno (2, 3-d) pyrimidine which 
showed as cytotoxic activity (1992). 










Chapter II                                                                  Literature Review 
 
Department of Pharmaceutical Chemistry  Page 15 
 
 FATHALLA et al., has synthesized a series of some pyrimidine derivatives with 
antibacterial and anticancer activity (2009). 







 DESENKO et al., has synthesized azolopyrimidine derivatives and compounds were 
evaluated for hypoglycemic activity (1995). 






 PADMA SHALE et al., have been reported naphtha (2, 1-b) furo (3, 2-d) pyrimidine 
derivative and evaluated for anti- inflammatory activity (2005). 










Chapter II                                                                  Literature Review 
 
Department of Pharmaceutical Chemistry  Page 16 
 
 ANU et al., has synthesized tri-substituted pyrimidine derivatives evaluated for their 
in-vitro antimalarial and anti -tubercular activities (1993). 






 VISHWANADHAN et al., reported the synthesis of some novel 5-substituted amino-
2, 4-diamino -8-chloro pyrimido-(4, 5-b) quinolines with antimalarial activity (2005). 






 SHERIFF et al., has synthesized 2-(benzoxazole -2-yl-amino)-3H-4-oxopyrimidines 
and screened for in-vitro anti HIV activity (2003) 
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 BRUNI et al., reported the synthesis of some new 2, 5-cycloamino 5H-benzopyrano 
(4, 3-d) pyrimidine which showed anti- inflammatory activity (1993). 
  
                              O
NN
NR 2
NR 1  
 PANDEYA et al., has synthesized some novel terpenylpyrimidines having anti 
leishmanial activity (2004). 







 JOUBRAN et al., has synthesized new aryl propanalamines which showed as 
antioxidant activity and neuroprotective agent (2003). 
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 MURUGAN et al.,  reported the synthesis of certain 2- substituted benzo-pyrimidine 
and evaluated their anticancer and cytotoxic activity (2004) 









 WERBEL et al., has synthesized a variety analogues of 2, 4-diamino 6-(arylthio) 
quinazolines with antimalarial and antitumour activities (1987). 








 KUMARASWAMY et al., has synthesized  and evaluated some angularly fused 
naphtho (2,1-b) furo (3,2-b) pyrimidines with increase in their diuretic and anti -
inflammatory activities (2006) 
 BECK et al., has synthesized a series of thiazolo (4,5-d) pyrimidine thione and 
evaluated their antipsychotic activity (2002). 
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 GOTTASOVA et al., reported a series of 2, 6-disubstituted 4-anilino quinazolines 
and evaluated for antibacterial activity (1990). 






 AVINASH et al., has synthesized certain 2-substituted benzopyrimidine and 
evaluated their cytotoxic activities (2004). 












 ASHOK et al., has synthesized a series of substituted pyrimidine derivative and 
tested for anti -inflammatory, analgesic, ulcerogenic activities (1993). 
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 PANDEYA et al., synthesized a series of novel substituted pyrimidine derivatives 
and evaluated their antimicrobial activity (2004). 











 AMIR et al., prepared and screened for the biological activities of some 4-(1H-
indole-3-yl)-6-phenyl-1, 2, 3, 4-tetrahydro pyrimidine-2-2 one thiones as potent anti- 
inflammatory agents (2007). 







 RAHAMAN et al., prepared some derivative of pyrimidine and evaluated their 
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3. SCOPE OF STUDY 
 Pyrimidine derivatives play a vital role providing exclusive clinical application and 
minimum toxic level. Recent observation also revealed, pyrimidines are closely 
related to nucleotides which can easily bind to biomolecules. So interested in 
selecting this nucleus for my present study.  
 The present study for synthesis of 1-substituted 2-amino-4-oxo -6-aryl 1, 4, 5, 6-
tetrahydropyrimidine -5-carbonitrile by Leuckart reaction. 
 These reactions were carried out earlier in the presence of amine, ketones and formic 
acid. I have introduced different ketones (Acetophenone & Benzophenone) with 
solvent free reaction condition, having lesser reaction time using Microwave 
irradiation and yield higher percentage of products. 
 From the literature point of view pyrimidine derivatives display a broad spectrum of 
biological activities. 
 The present work have been design to carry out synthesis of 1-substituted  tetrahydro 
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PLAN OF WORK 
 To design lead molecule of 2-amino-4-oxo-6-aryl 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile by molinspiration, chemdoodle, 
chemsketch. 
 The compounds were synthesized by Leuckart reaction using Microwave 
irradiation. 
 These synthesized compounds of 1-substistuted tetrahydropyrimidine 
derivatives were confirmed using TLC. 
 To carry out the preliminary test such as melting point and solubility. 
 To confirm the structure of synthesized compounds by IR, MASS, 1H NMR 
spectroscopy. 
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4. MOLECULAR DESIGN  
 MOLINSPIRATION 
 This software is used to calculate the following properties 
 Molecular weight 
 Lipophilicity 
 Bioactivity score 
 i) GPCR ligand 
 ii) Ion channel modulator 
 iii) Kinase inhibitor 
 iv) Nuclear receptor ligand 
v) Protease inhibitor 
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Molinspiration property engine v2013.09
 
miLogP         2.892 
TPSA           82.488 
natoms         26.0 
MW             366.852 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          4 




Molinspiration bioactivity score v2011.06
GPCR ligand                -0.16 
Ion channel modulator      -0.32 
Kinase inhibitor           -0.50 
Nuclear receptor ligand    -0.72 
Protease inhibitor          0.09 
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Molinspiration property engine v2013.09
 
miLogP         2.271 
TPSA           91.722 
natoms         27.0 
MW             362.433 
nON            6 
nOHNH          2 
nviolations    0 
nrotb          5 




Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.19 
Ion channel modulator      -0.37 
Kinase inhibitor           -0.50 
Nuclear receptor ligand    -0.69 
Protease inhibitor          0.07 
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Molinspiration property engine v2013.09 
 
miLogP         2.316 
TPSA           85.726 
natoms         28.0 
MW             375.476 
nON            6 
nOHNH          2 
nviolations    0 
nrotb          5 




Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.15 
Ion channel modulator      -0.31 
Kinase inhibitor           -0.41 
Nuclear receptor ligand    -0.64 
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Molinspiration property engine v2013.09
 
miLogP         2.97 
TPSA           82.488 
natoms         27.0 
MW             358.445 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          5 





Molinspiration bioactivity score v2011.06
GPCR ligand                -0.02 
Ion channel modulator      -0.19 
Kinase inhibitor           -0.29 
Nuclear receptor ligand    -0.38 
Protease inhibitor          0.39 
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Molinspiration property engine v2013.09
 
miLogP         2.214 
TPSA           82.488 
natoms         25.0 
MW             332.407 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          4 




Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.16 
Ion channel modulator      -0.32 
Kinase inhibitor           -0.50 
Nuclear receptor ligand    -0.72 
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Molinspiration property engine v2013.09
 
miLogP         4.111 
TPSA           82.488 
natoms         31.0 
MW             428.923 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          5 
volume         380.016 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.13 
Ion channel modulator      -0.23 
Kinase inhibitor           -0.49 
Nuclear receptor ligand    -0.59 
Protease inhibitor          0.01 
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Molinspiration property engine v2013.09
 
miLogP         3.489 
TPSA           91.722 
natoms         32.0 
MW             424.504 
nON            6 
nOHNH          2 
nviolations    0 
nrotb          6 
volume         392.025 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.16 
Ion channel modulator      -0.28 
Kinase inhibitor           -0.49 
Nuclear receptor ligand    -0.57 
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Molinspiration property engine v2013.09
 
miLogP         3.535 
TPSA           85.726 
natoms         33.0 
MW             437.547 
nON            6 
nOHNH          2 
nviolations    0 
nrotb          6 




Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.12 
Ion channel modulator      -0.24 
Kinase inhibitor           -0.42 
Nuclear receptor ligand    -0.53 
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Molinspiration property engine v2013.09
 
miLogP         4.189 
TPSA           82.488 
natoms         32.0 
MW             420.516 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          6 
volume         393.896 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.00 
Ion channel modulator      -0.11 
Kinase inhibitor           -0.29 
Nuclear receptor ligand    -0.27 
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Molinspiration property engine v2013.09
 
miLogP         3.433 
TPSA           82.488 
natoms         30.0 
MW             394.478 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          5 




Molinspiration bioactivity score v2011.06
GPCR ligand                -0.13 
Ion channel modulator      -0.23 
Kinase inhibitor           -0.49 
Nuclear receptor ligand    -0.59 
Protease inhibitor          0.05 
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This software is used to calculate the following properties. 
 Molecular weight 
 Hydrogen bond donor 
 Hydrogen bond acceptor 
 Lipophilicity 
 Molar refractivity 
 
Lipinski’s rule: 
Lipinski’s rule of five states that, in general, an orally active drug has: 
1. Not more than 5 hydrogen bond donors. 
2. Not more than 10 hydrogen bond acceptors. 
3. Molecular weight below 500 g / mol. 
4. Partition co-efficient log P less than 5. 
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2-amino -6-(4-chloro phenyl)-4-oxo -1-(1-phenylethyl)1,4,5,6  
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                       2-amino -6-[4-(dimethyl amino) phenyl] -4-oxo -1-(1-phenylethyl) 1,4,5,6 
                       - tetrahydropyrimidine -5-carbonitrile 
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Lipinski’s Rule of 5 Violations Count = 0         
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                           2-amino -4-oxo -6-phenyl -1-(1-phenylethyl) 1,4,5,6 
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 D – E8 
        
    2-amino -6-[4-(dimethyl amino) phenyl] -1-(diphenylmethyl) -4-oxo 
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D – E9 
             2-amino -1-(diphenylmethyl) -4-oxo -6-[(E)-2-phenylethenyl] 
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                       2-amino -1-(diphenylmethyl) -4-oxo -6-phenyl 1,4,5,6 
                       -tetrahydropyrimidine -5-carbonitrile                                     
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CHEMSKETCH 










2-amino -6-(4-chloro phenyl)-4-oxo -1-(1-phenylethyl)1,4,5,6  
-tetrahydro pyrimidine  -5- carbonitrile 
 
Molecular Formula  = C19H17ClN4O 
Formula Weight   = 352.81748 
Composition   = C(64.68%) H(4.86%) Cl(10.05%) 
N(15.88%) O(4.53%) 
Molar Refractivity  = 98.56 ± 0.5 cm3 
Molar Volume   = 267.6 ± 7.0 cm3 
Parachor    = 718.7 ± 8.0 cm3 
Index of Refraction  = 1.657 ± 0.05 
Surface Tension   = 52.0 ± 7.0 dyne/cm 
Density    = 1.31 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 39.07 ± 0.5 10-24cm3 
Monoisotopic Mass  = 352.109089 Da 
Nominal Mass   = 352 Da 
Average Mass   = 352.8175 Da 
M+     = 352.10854 Da 
M-     = 352.109637 Da 
[M+H]+    = 353.116365 Da 
[M+H]-    = 353.117463 Da 
[M-H]+    = 351.100715 Da 
[M-H]-    = 351.101812 Da 
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2-amin-6-(4-methoxy phenyl) -4-oxo -1- (1-phenylethyl) 1,4,5,6- 
tetrahydropyrimidine -5-carbonitrile 
 
Molecular Formula  = C20H20N4O2 
Formula Weight   = 348.3984 
Composition   =  C(68.95%) H(5.79%) N(16.08%) 
O(9.18%) 
Molar Refractivity  = 99.78 ± 0.5 cm3 
Molar Volume   = 280.0 ± 7.0 cm3 
Parachor    = 740.1 ± 8.0 cm3 
Index of Refraction  = 1.631 ± 0.05 
Surface Tension   = 48.8 ± 7.0 dyne/cm 
Density    = 1.24 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 39.55 ± 0.5 10-24cm3 
Monoisotopic Mass  = 348.158626 Da 
Nominal Mass   = 348 Da 
Average Mass   = 348.3984 Da 
M+     = 348.158077 Da 
M-     = 348.159174 Da 
[M+H]+    = 349.165902 Da 
[M+H]-    = 349.167 Da 
[M-H]+    = 347.150252 Da 
[M-H]-    = 347.151349 Da 
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                            2-amino -6-[4-(dimethyl amino) phenyl] -4-oxo -1-(1-phenylethyl) 1,4,5,6- 
                        tetrahydropyrimidine -5-carbonitrile 
 
Molecular Formula  = C21H23N5O 
Formula Weight   = 361.44022 
Composition   =  C(69.78%) H(6.41%) N(19.38%) 
O(4.43%) 
Molar Refractivity  = 106.77 ± 0.5 cm3 
Molar Volume   = 299.5 ± 7.0 cm3 
Parachor    = 786.2 ± 8.0 cm3 
Index of Refraction  = 1.631 ± 0.05 
Surface Tension   = 47.4 ± 7.0 dyne/cm 
Density    = 1.20 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 42.32 ± 0.5 10-24cm3 
Monoisotopic Mass  = 361.19026 Da 
Nominal Mass   = 361 Da 
Average Mass   = 361.4402 Da 
M+     = 361.189712 Da 
M-     = 361.190809 Da 
[M+H]+    = 362.197537 Da 
[M+H]-    = 362.198634 Da 
[M-H]+    = 360.181887 Da 
[M-H]-    = 360.182984 Da 
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2-amino -4-oxo [(E)-2-phenylethenyl] -1-(1-phenylethyl)    
1,4,5,6-tetrahydropyrimidine -5-carbonitrile 
 
Molecular Formula  = C21H20N4O 
Formula Weight  = 344.4097 
Composition   =  C(73.23%) H(5.85%) N(16.27%) O(4.65%) 
Molar Refractivity  = 103.18 ± 0.5 cm3 
Molar Volume  = 290.4 ± 7.0 cm3 
Parachor   = 767.1 ± 8.0 cm3 
Index of Refraction  = 1.628 ± 0.05 
Surface Tension  = 48.6 ± 7.0 dyne/cm 
Density   = 1.18 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 40.90 ± 0.5 10-24cm3 
Monoisotopic Mass  = 344.163711 Da 
Nominal Mass  = 344 Da 
Average Mass  = 344.4097 Da 
M+    = 344.163163 Da 
M-    = 344.16426 Da 
[M+H]+   = 345.170988 Da 
[M+H]-   = 345.172085 Da 
[M-H]+   = 343.155338 Da 
[M-H]-   = 343.156435 Da 
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                             2-amino -4-oxo -6-phenyl -1-(1-phenylethyl) 1,4,5,6- 
                           tetrahydropyrimidine -5- carbonitrile 
 
Molecular Formula  = C19H18N4O 
Formula Weight   = 318.37242 
Composition   =  C(71.68%) H(5.70%) N(17.60%) 
O(5.03%) 
Molar Refractivity  = 93.96 ± 0.5 cm3 
Molar Volume   = 258.3 ± 7.0 cm3 
Parachor    = 689.9 ± 8.0 cm3 
Index of Refraction  = 1.647 ± 0.05 
Surface Tension   = 50.8 ± 7.0 dyne/cm 
Density    = 1.23 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 37.25 ± 0.5 10-24cm3 
Monoisotopic Mass  = 318.148061 Da 
Nominal Mass   = 318 Da 
Average Mass   = 318.3724 Da 
M+     = 318.147513 Da 
M-     = 318.14861 Da 
[M+H]+    = 319.155338 Da 
[M+H]-    = 319.156435 Da 
[M-H]+    = 317.139688 Da 
[M-H]-    = 317.140785 Da 
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                           2-amino -6-(4-chloro phenyl) -1-(diphenylmethyl) -4-oxo 1,4,5,6‐ 
                        tetrahydropyrimidine -5-carbonitrile 
 
Molecular Formula  = C24H19ClN4O 
Formula Weight   = 414.88686 
Composition   =  C(69.48%) H(4.62%) Cl(8.55%) 
N(13.50%) O(3.86%) 
Molar Refractivity  = 119.25 ± 0.5 cm3 
Molar Volume   = 320.2 ± 7.0 cm3 
Parachor    = 864.5 ± 8.0 cm3 
Index of Refraction  = 1.667 ± 0.05 
Surface Tension   = 53.0 ± 7.0 dyne/cm 
Density    = 1.29 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 47.27 ± 0.5 10-24cm3 
Monoisotopic Mass  = 414.124739 Da 
Nominal Mass   = 414 Da 
Average Mass   = 414.8869 Da 
M+     = 414.12419 Da 
M-     = 414.125288 Da 
[M+H]+    = 415.132015 Da 
[M+H]-    = 415.133113 Da 
[M-H]+    = 413.116365 Da 
[M-H]-    = 413.117463 Da 
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2-amino -1-(diphenylmethyl) -6-(4-methoxy phenyl) -4-oxo 1,4,5,6- 
tetrahydropyrimidine -5-carbonitrile 
 
Molecular Formula  = C25H22N4O2 
Formula Weight   = 410.46778 
Composition   =  C(73.15%) H(5.40%) N(13.65%) 
O(7.80%) 
Molar Refractivity  = 120.46 ± 0.5 cm3 
Molar Volume   = 332.6 ± 7.0 cm3 
Parachor    = 885.9 ± 8.0 cm3 
Index of Refraction  = 1.644 ± 0.05 
Surface Tension   = 50.3 ± 7.0 dyne/cm 
Density    = 1.23 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 47.75 ± 0.5 10-24cm3 
Monoisotopic Mass  = 410.174276 Da 
Nominal Mass   = 410 Da 
Average Mass   = 410.4678 Da 
M+     = 410.173727 Da 
M-     = 410.174825 Da 
[M+H]+    = 411.181552 Da 
[M+H]-    = 411.18265 Da 
[M-H]+    = 409.165902 Da 
[M-H]-    = 409.167 Da 
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2-amino -6-[4-(dimethyl amino) phenyl] -1-(diphenylmethyl) -4-oxo 
 1,4,5,6-tetrahydropyrimidine -5-carbonitrile 
 
Molecular Formula    = C26H25N5O 
Formula Weight             = 425.5096 
Composition             =  C(73.74%) H(5.95%) N(16.54%) 
O(3.78%) 
Molar Refractivity    = 127.45 ± 0.5 cm3 
Molar Volume             = 352.1 ± 7.0 cm3 
Parachor                      = 932.0 ± 8.0 cm3 
Index of Refraction        = 1.643 ± 0.05 
Surface Tension            = 49.0 ± 7.0 dyne/cm 
Density                     = 1.20 ± 0.1 g/cm3 
Dielectric Constant   = Not available 
Polarizability            = 50.52 ± 0.5 10-24cm3 
Monoisotopic Mass   = 423.20591 Da 
Nominal Mass            = 423 Da 
Average Mass          = 423.5096 Da 
M+                               = 423.205362 Da 
M-                               = 423.206459 Da 
[M+H]+                      = 424.213187 Da 
[M+H]-                      = 424.214284 Da 
[M-H]+                      = 422.197537 Da 
[M-H]-                      = 422.198634 Da 
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2-amino -1-(diphenylmethyl) -4-oxo -6-[(E)-2-phenylethenyl] 
                        1,4,5,6-tetrahydropyrimidine -5-carbonitrile 
Molecular Formula  = C26H22N4O 
Formula Weight  = 406.47908 
Composition   =  C(76.83%) H(5.46%) N(13.78%) O(3.94%) 
Molar Refractivity  = 123.86 ± 0.5 cm3 
Molar Volume  = 343.1 ± 7.0 cm3 
Parachor   = 912.9 ± 8.0 cm3 
Index of Refraction  = 1.641 ± 0.05 
Surface Tension  = 50.1 ± 7.0 dyne/cm 
Density   = 1.18 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 49.10 ± 0.5 10-24cm3 
Monoisotopic Mass  = 406.179361 Da 
Nominal Mass  = 406 Da 
Average Mass  = 406.4791 Da 
M+    = 406.178813 Da 
M-    = 406.17991 Da 
[M+H]+   = 407.186638 Da 
[M+H]-   = 407.187735 Da 
[M-H]+   = 405.170988 Da 
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                       2-amino -1-(diphenylmethyl) -4-oxo -6-phenyl 1,4,5,6 
                       -tetrahydropyrimidine -5-carbonitrile  
Molecular Formula  = C24H20N4O 
Formula Weight  = 380.4418 
Composition   =  C(75.77%) H(5.30%) N(14.73%) O(4.21%) 
Molar Refractivity  = 114.65 ± 0.5 cm3 
Molar Volume  = 311.0 ± 7.0 cm3 
Parachor             = 835.6 ± 8.0 cm3 
Index of Refraction  = 1.658 ± 0.05 
Surface Tension  = 52.1 ± 7.0 dyne/cm 
Density             = 1.22 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability             = 45.45 ± 0.5 10-24cm3 
Monoisotopic Mass  = 380.163711 Da 
Nominal Mass  = 380 Da 
Average Mass  = 380.4418 Da 
M+                        = 380.163163 Da 
M-                        = 380.16426 Da 
[M+H]+             = 381.170988 Da 
[M+H]-             = 381.172085 Da 
[M-H]+             = 379.155338 Da 
[M-H]-             = 379.156435 Da 
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D – E1 352.81 2.89 1 5 98.9070 ALL 
D – E2 348.90 3 1 6 100.1620 ALL 
D – E3 361.44 3.3 1 6 106.9560 ALL 
D –E4 344.41 3.22 1 5 103.7560 ALL 
D – E5 318.37 3 2 5 94.2470 ALL 
D – E6 414.88 3.44 2 5 119.6350 ALL 
D – E7 410.46 3.5 1 6 120.89 ALL 
D – E8 425.52 3.6 1 6 127.430 ALL 
D – E9 406.47 3.77 1 5 124.2490 ALL 





         
      EXPERIMENTAL     
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                               5. EXPERIMENTAL PROCEDURE 
 SCHEME OF REACTION 
 STEP 1: 





















2-amino 6_ aryl_4_ oxo 1,4,5,6_ tetrahydropyrimidine 5_ carbonitrile
Aromatic aldehyde
 
1. P-Chloro benzaldehyde 
2. P-Methoxy benzaldehyde 
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Mechanism: 
 Aromatic aldehyde reacts with ethyl cyanoacetate to form arylmethylene ethyl 
cyanoactate. 
 Subsequently added with quanidine fallowed by cyclization and tautomarisation to 
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2-amino 6_ aryl_4_ oxo 1,4,5,6_ tetrahydropyrimidine 5_ carbonitrile
Formic acid




            R1              R2 
D –E1 to D –E5 
 
            CH3            C6H5 
D –E6 to D- E10 
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Mechanism 
 Amine reacst with protonated ketone to give iminium ion. 
 The iminium ion then react with formic acid to give methylated ammonium ion 
and release CO2 gas, where formic acid act as a reducing agent or hydride transfer 
reagent. 
 This CO2 gas leads the synthesis process to the next level of synthesis. 
 In this stage ammonium ion gets deprotonated to form final methylated amine 
product. 
 If reaction occurs with primary amine same process follows twice to reach the 
tertiary amine as a final product. 
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Synthesis of 2-amino -4-oxo- 6-(4-choloro phenyl) 1, 4, 5, 6- 
tetrahydropyrimidine -5-carbonitrile 
     CHEMICALS REQUIRED 
 Guanidine nitrate                -1.5mmol 
 Ethyl cyanoacetate               -1.2mmo 
 P-Chloro benzaldehyde       -1.0mmol  
 Potassium carbonate            -Q.S 
 
PROCEDURE 
A mixture of p-chloro benzaldehyde (1mmol), guanidine nitrate (1.5mmol), 
ethyl cyanoacetate (1.2mmol) and catalytic amount of potassium carbonate was taken 
in a round bottom flask (100ml) with water as a solvent and refluxed at 100◦C. The 
progress of the reaction was monitored by TLC.  The solution was poured into ice 
cold water. After the completion of the reaction the solid product was collected by 
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4-chlorobenzaldehyde ethyl cyanoacetate guanidine
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COMPOUND –B 
Synthesis of 2-amino -4-oxo -6-(4-methoxy phenyl) 1, 4, 5, 6- 
 tetrahydropyrimidine -5-carbonitrile 
CHEMICALS REQUIRED 
 Guanidine nitrate                   -1.5mmol 
 Ethyl cyanoacetate                 -1.2mmol 
 P-Methoxy benzaldehyde       -1.0mmol   
 Potassium carbonate               -Q.S 
 
PROCEDURE 
A mixture of p-methoxy benzaldehyde (1mmol), guanidine nitrate (1.5mmol), 
ethyl cyanoacetate (1.2mmol) and catalytic amount of potassium carbonate was taken 
in a round bottom flask (100ml) with water as a solvent and refluxed at 100◦C. The 
progress of the reaction was monitored by TLC.  The solution was poured into ice 
cold water. After the completion of the reaction the solid product was collected by 
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COMPOUND –C 
Synthesis of 2-amino6-[4-(dimethylamino) phenyl]-4-oxo 1, 4, 5, 6   
- tetrahydropyrimidine -5-carbonitrile 
CHEMICALS REQUIRED 
 Guanidine nitrate                                 -1.5mmol 
 Ethyl cyanoacetate                                -1.2mmol 
 P-Dimethylamino benzaldehyde          -1.0mmol    
 Potassium carbonate                             -Q.S 
 
PROCEDURE 
A mixture of p-dimethylamino benzaldehyde (1mmol), guanidine nitrate 
(1.5mmol), ethyl cyanoacetate (1.2mmol) and catalytic amount of potassium 
carbonate was taken in a round bottom flask (100ml) with water as a solvent and 
refluxed at 100◦C.The progress of the reaction was monitored by TLC.  The solution 
was poured into ice cold water. After the completion of the reaction the solid product 
was collected by filteration.  The product was dried and recrystallized from hot 
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COMPOUND-D 
Synthesis of 2-amino-4-oxo-6-[(E)-2 phenyl ethenyl] 1, 4, 5, 6- 
tetrahydropyrimidine -5-carbonitrile 
 CHEMICALS REQUIRED 
 Guanidine nitrate                               -1.5mmol 
 Ethyl cyanoacetate                              -1.2mmol 
 Cinnamaldehyde -1.0mmol                -1.0mmol 
 Potassium carbonate                           -Q.S 
 
PROCEDURE 
A mixture of cinnamaldehyde (1.0mmol), guanidine nitrate (1.5mmol), ethyl 
cyanoacetate (1.2mmol) and catalytic amount of potassium carbonate was taken in a 
round bottom flask (100ml) with water as a solvent and refluxed at 100◦C. The 
progress of the reaction was monitored by TLC.  The solution was poured into ice 
cold water. After the completion of the reaction the solid product was collected by 
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COMPOUND-E 
Synthesis 0f 2-amino -4-oxo -6-phenyl 1, 4, 5, 6-tetrahydropyrimidine                     
-5-carbonitrile  
CHEMICALS REQUIRED 
 Guanidine nitrate                               -1.5mmol 
 Ethyl cyanoacetate                             -1.2mmol 
 Benzaldehyde                                     -1.0mmol 
 Potassium carbonate                           -Q.S 
 
PROCEDURE 
A mixture of benzaldehyde (1.0mmol), guanidine nitrate (1.5mmol), ethyl 
cyanoacetate (1.2mmol) and catalytic amount of potassium carbonate was taken in a 
round bottom flask (100ml) with water as a solvent and refluxed at 100◦C. The 
progress of the reaction was monitored by TLC.  The solution was poured into ice 
cold water. After the completion of the reaction the solid product was collected by 
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PREPARATION OF 2-AMINO-4-OXO -6-PHENYL 1, 4, 5, 6 - 
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COMPOUND DERIVATIVES     
COMPOUND D –E1 
 
CHEMICALS REQUIRED 
  Acetophenone                                                               -1.5ml 
  2-amino -6-(4-chloro phenyl) -4-oxo 
       1, 4, 5, 6-tetrahydroPyrimidine -5-carbonitrile            -1.5gm 
 Formic acid                                                                   -1.5ml 
PROCEDURE 
Acetophenone (1.5ml), 2-amino -6-(4-chloro phenyl) -4-oxo 1,4,5,6-                       
tetrahydropyrimidine -5-carbonitrile (1.5gm) and formic acid (1.5ml) was irradiated in 
microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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COMPOUND D – E2 
CHEMICALS REQUIRED 
 Acetophenone                                                           -1.5ml 
 2-amino -6-(4-methoxy phenyl)- 4- oxo 
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile        -1.5gm 
 Formic acid                                                               -1.5ml 
PROCEDURE 
Acetophenone (1.5ml),2-amino -6-(4-methoxy phenyl) -4-oxo 1,4,5,6-               
tetrahydropyrimidine -5-carbonitrile(1.5gm) and formic acid(1.5ml) was irradiated in 
microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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COMPOUND D – E3 
CHEMICALS REQUIRED 
 Acetophenone                                                         -1.5ml 
 2-amino -6-(4-dimethyl amino phenyl)- 4- oxo 
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile      -1.5gm 
 Formic acid                                                             -1.5ml 
PROCEDURE: 
Acetophenon (1.5ml),2-amino -6-(4-dimethyl amino phenyl) -4-oxo 1,4,5,6 -
tetrahydropyrimidine -5-carbonitrile(1.5gm) and formic acid(1.5ml) was irradiated in 
microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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COMPOUND D – E4 
CHEMICALS REQUIRED 
 Acetophenone                                                           -1.5ml 
 2-amino - 4- oxo -6-[(E)-2-phenyl ethenyl] 
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile        -1.5gm 
 Formic acid                                                               -1.5ml 
PROCEDURE 
Acetophenone (1.5ml),2-amino -4-oxo -6-[(E)-2-phenyl ethenyl] 1,4,5,6-                    
tetrahydropyrimidine -5-carbonitrile(1.5gm) and formic acid(1.5ml) was irradiated in 
microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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                                               COMPOUND D –E5 
CHEMICALS REQUIRED 
 Acetophenone                                                           -1.5ml 
 2-amino - 4- oxo -6-phenyl  
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile        -1.5gm 
 Formic acid                                                              -1.5ml 
PROCEDURE 
Acetophenone (1.5ml), 2-amino -4-oxo -6-phenyl 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile(1.5gm) and formic acid(1.5ml) was irradiated in 
microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 









Chapter V                                                                   Experimental Procedure  
 





























Chapter V                                                                   Experimental Procedure  
 
Department of Pharmaceutical chemistry  Page 82 
 
 
                                           COMPOUND D –E6 
CHEMICALS REQUIRED 
 Benzophenone                                                        -1.5ml 
 2-amino -6-(4-chloro phenyl) -4-oxo  
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile     -1.5gm 
  Formic acid                                                           -1.5ml 
PROCEDURE 
Benzophenone (1.5ml), 2-amino -6-(4-chloro phenyl) 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile (1.5gm) and formic acid (1.5ml) was irradiated 
in microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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                                             COMPOUND D –E7 
CHEMICALS REQUIRED 
 Benzophenone                                                           -1.5ml 
 2-amino -6-(4-methoxy phenyl) -4-oxo 
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile        -1.5gm 
  Formic acid                                                              -1.5ml 
PROCEDURE: 
Benzophenone (1.5ml), 2-amino -6-(4-methoxy phenyl) 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile (1.5gm) and formic acid(1.5ml) was irradiated in 
microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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COMPOUND D - E7
Leuckart reaction
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                                        COMPOUND D –E8 
CHEMICALS REQUIRED 
 Benzophenone                                                          -1.5ml 
 2-amino -6-(4-dimethyl amino phenyl)- 4- oxo 
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile       -1.5gm 
  Formic acid                                                             -1.5ml 
PROCEDURE 
Benzophenone (1.5ml), 2-amino -6-(4-dimethyl amino phenyl) -4-oxo 1,4,5,6-                       
tetrahydropyrimidine -5-carbonitrile (1.5gm) and formic acid (1.5ml) was irradiated 
in microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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COMPOUND D - E8
Leuckart reaction
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                                         COMPOUND D –E9 
CHEMICALS REQUIRED 
 Benzophenone      -1.5ml 
 2-amino - 4- oxo -6-[(E)-2-phenyl ethenyl] 
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile   -1.5gm 
  Formic acid      -1.5ml 
PROCEDURE 
Benzophenone (1.5ml), 2-amino -4-oxo -6-[(E)-2-phenyl ethenyl] 1,4,5,6-                        
tetrahydropyrimidine -5-carbonitrile (1.5gm) and formic acid (1.5ml) was irradiated 
in microwave at 80◦C for 4minutes in equimolar quantities. The solution was obtained 
and then cooled in ice bath until the crystals are formed. The crude product was 
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        2-amino -1-(diphenyl methyl) -4-oxo -6-[(E)-2-phenyl ethenyl] 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
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                                            COMPOUND D –E10  
CHEMICALS REQUIRED 
 Benzophenone     -1.5ml 
 2-amino - 4- oxo -6-phenyl  
 1, 4, 5, 6-tetrahydropyrimidine -5-carbonitrile  -1.5gm 
 Formic acid      -1.5ml 
PROCEDURE 
 Benzophenone (1.5ml), 2-amino -4-oxo -6-phenyl 1, 4, 5, 6-
tetrahydropyrimidine -5-carbonitrile (1.5gm) and formic acid (1.5ml) was irradiated 
in microwave at 80◦C for 4 minutes in equimolar quantities. The solution was 
obtained and then cooled in ice bath until the crystals are formed. The crude product 
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6. ANALYTICAL DATA OF SYNTHESIZED COMPOUNDS 
PHYSICAL DATA ANALYSIS 




   D – E1 2-amino -6-(4-chloro phenyl)-4-oxo -1-(1-phenylethyl)1,4,5,6-
tetrahydropyrimidine  -5-carbonitrile 
   D – E2 2-amin  -6-(4-methoxy phenyl) -4-oxo -1- (1-phenylethyl) 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
   D – E3 2-amino -6-[4-(dimethyl amino) phenyl] -4-oxo -1-(1-phenylethyl) 
1,4,5,6-tetrahydropyrimidine -5-carbonitrile 
   D – E4 2-amino -4-oxo [(E)-2-phenylethenyl] -1-(1-phenylethyl) 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
   D – E5 2-amino -4-oxo -6-phenyl -1-(1-phenylethyl) 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
   D – E6 2-amino -6-(4-chloro phenyl) -1-(diphenylmethyl) -4-oxo 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
   D – E7 2-amino -1-(diphenylmethyl) -6-(4-methoxy phenyl) -4-oxo 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
   D – E8 2-amino -6-[4-(dimethyl amino) phenyl] -1-(diphenylmethyl) -4-oxo 
1,4,5,6-tetrahydropyrimidine -5-carbonitrile 
   D – E9 2-amino -1-(diphenylmethyl) -4-oxo -6-[(E)-2-phenylethenyl] 1,4,5,6-
tetrahydropyrimidine -5-carbonitrile 
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                                     PHYSICAL DATA ANALYSIS 








     D – E1 
 
C19H17ClN4O        352.82 
     D – E2 
 
C20H20N4O2        348.39 
     D – E3 
 
C21H23N5O        361.44 
     D – E4 
 
C21H20N4O        344.40 
     D – E5 
 
C19H18N4O        318.37 
     D – E6 
 
C24H19ClN4O        414.88 
     D – E7 
 
C25H22N4O2        410.46 
     D – E8 
 
C26H27N5O        425.52 
     D – E9 
 
C26H22N4O        406.47 
     D – E10 
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PHYSICAL DATA ANALYSIS 








D – E1 CHCl3 SOLID/PALE YELLOW 75% 
D – E2 CHCl3 SOLID/YELLOW 68% 
D – E3 CHCl3 SOLID/YELLOW 82% 
D – E4 CHCl3 SOLID/ORANGE 62% 
D – E5 CHCl3 SOLID/YELLOW 55% 
D – E6 CHCl3 SOLID/YELLOW 80% 
D – E7 CHCl3 SOLID/YELLOW 64% 
D – E8 CHCl3 SOLID/YELLOW 74% 
D – E9 CHCl3 SOLID/PALE YELLOW 58% 
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Table No: 5 
COMPOUND  
CODE 
 ℅C  ℅H ℅N ℅O ℅ Cl 
     D – E1 64.68℅ 4.86℅ 15.88℅ 4.53℅ 10.05 
     D – E2 68.95℅ 15.79℅ 16.08℅ 9.18℅    - 
     D – E3 69.78℅ 6.41℅ 19.38℅ 4.43℅     - 
     D – E4 73.23℅ 5.85℅ 16.27℅ 4.65℅     - 
     D – E5 71.68℅ 5.7℅ 17.6℅ 5.03     - 
     D – E6 69.48℅ 4.62℅ 13.3℅ 3.86 8.55℅ 
     D – E7 73.15℅ 5.4℅ 13.65℅ 7.8℅     - 
     D – E8 73.39℅ 6.4℅ 16.46℅ 3.76℅     - 
     D – E9 76.83℅ 5.46℅ 13.78℅ 3.94℅     - 
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MELTING POINT ANALYSIS 
 
Melting point was determined by using open end capillary tube. 
The melting point of synthesized compounds is given in the Table No: 6 
 
     S.NO    COMPOUND MELTING POINT 0C 
        1         D – E1             174 
        2         D – E 2             180 
        3         D – E3             236 
        4         D – E4             240 
        5         D – E5             225 
        6         D – E6             252 
        7         D – E7             263 
        8         D – E8             245 
        9         D – E9             208 
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THIN LAYER CHROMATOGRAPHY 
The principle of separation is adsorption. Thin layer chromatography was carried out by 
using silica gel(0.5mm thickness) coated over the glass plate (12x20 cm) as stationary phase, 
 CHCl3: CH3OH (9:1) or CHCl3: C2H5OH (6:4) as mobile phase and spots were visualized by 
iodine vapours. 
Mobile Phase used 
Chloroform       : Methanol 
9               : 1 
Table No: 7 
COMPOUND CODE       Rf  VALUE 
      D – E1           0.74 
      D – E2           0.68 
      D – E3           0.75 
      D – E4           0.65 
      D – E5           0.64 
      D – E6           0.67    
      D – E7           0.70 
      D – E8           0.72 
      D – E9           0.63 
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7. SPECTRAL ANALYSIS14, 49 
7.1 IR SPECTROSCOPY 
 
 The range of electromagnetic radiation between 0.8µ and 500µ is termed as infrared 
radiation. The IR spectrum is represented with percent transmittance (℅T) in the 
ordinate and the wave number (cm-1) in the abscissa. 
 The IR radiation refers to broadly to that region of electromagnetic spectrum which 
lies between visible and microwave region. IR region is divided into 3 sections 
  i) Mid IR region – wave length 25µ to 2.5µ 
  ii) Near IR region – wave length 0.8µ to 2.5µ 
 iii) Far IR region    - wave length 25µ to1000µ 
 The most commonly used region of IR spectrum in pharmaceutical chemistry between 
4000- 400 cm-1 
 IR spectroscopy is one of the most powerful analytical techniques which offer the 
possibility of chemical identification. One of the most advantages of IR over the other 
usual methods of structural analysis (X-ray diffraction, electron spin resonance etc.) is 
that it provides useful information about the structure molecule quickly. 
 IR spectroscopy can solve many problems in organic chemistry and coordination 
chemistry. 
 IR spectroscopy can be used identification of functional group, drug substance and 
impurities in a drug sample. 
PELLET TECHNIQUE 
 The solid sample is mixed with powdered potassium bromide and triturate in a 
smooth mortar. The mixture is uniformly spread over the dye and compressed into a thin 
transparent pellet using hydraulic press under pressure 15000 psi. The IR spectral data of the 
synthesized compounds were recorded on Fourier Tranform IR spectrometer in the ranges of 
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    D – E1 C= O str (Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C- N str 
C-H str (methyl) 
Ar-Cl 
            1612 
            3433 
            1446 
            2223 
            1309 
            2872 
            709 
    D – E2 C= O str (Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
C-H str (methyl) 
OCH3  
           1637 
           3368 
           1502 
           2216 
           1275 
           2943 
           2834 
    D – E3 C= O str (Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
C-H str (methyl) 
N(CH3)2 
           1660 
           3730 
           1431 
           2208 
           1371 
           2860 
           1327 
    D – E4 C= O str (Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-Nstr 
C-H str (methyl) 
C=Cstr (alkene) 
=CH str 
           1612 
           3300 
           1448 
           2220 
           1085 
           2852 
           1658 
           3134 
    D – E5 C= O str (Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-Nstr 
C-H str (methyl) 
Ar-H str 
           1598 
           3311 
           1444 
           2223 
           1010 
           2850 
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    D –E6 
C= O str(Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
Ar-Cl 
           1658 
           3315 
           1481 
           2223 
           1001 
             638 
    D – E7 C= O str(Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
OCH3 
           1654 
           3414 
           1598 
           2216 
           1018 
            846 
    D – E8 C= O str(Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
N(CH3)2 
           1548 
           3458 
           1562 
           2250 
           1064 
           1317 
    D – E9 C= O str(Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
C=C str (alkene) 
=CH str 
           1610 
           3380 
           1597 
           2220 
           1085 
           1658 
           3028 
    D – E10 C= O str(Ketone) 
N-H str(Ar10 Amine) 
C=N str 
C≡N str (Nitrile) 
C-N str 
Ar-H str 
           1658 
           3309 
           1442 
           2223 
           1010 
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 Mass spectroscopy is an analytical techniques which can provide more 
information Concerning the molecular mass of organic and inorganic compounds. 
 Mass spectroscopy is most accurate, speed, reliability and expensive instrument. 
 In this technique, molecules are bambarded with a beam of energetic electrons 
which produce an ionic molecule. The resulting assortment of charged particles is 
then separated according to their masses and some ions which are positive ions. 
 Each kind of ions has particular ratio of mass to charge, i.e-m/e ratio. The 
molecular ion is called as parent ion and the largest peak in the structure is called 
as base peak. 
 The m/e value of the parent ion is equal to the molecular mass of the compound. 
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MASS SPECTRAL DATA 
Table No: 9 
COMPOUND CODE MOLECULAR IONS 
D – E1 352.82 
D – E2 348.39 
D – E3 361.44 
D – E4 344.40 
D – E5 318.37 
D – E6 414.88 
D – E7 410.46 
D – E8 425.52 
D – E9 406.47 
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D – E1 
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D – E3 
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D – E5 
 
 
D – E6 
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D – E7 
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D – E9 
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7.3. NMR SPECTROSCOPY 
 NMR spectroscopy is an analytical method for determining the structural elucidation 
of organic compounds and quantitative analysis included in hydrogen analysis, 
moisture analysis, iodine value. 
 Nuclear Magnetic Resonance spectroscopy is the study of spin changes at the nuclear 
level when radio frequency energy is absorbed in the presence of magnetic field. 
When proton (hydrogen) is studied then it is called as proton magnetic resonance. 
 Proton or Nuclei with odd mass number only gives NMR spectra. eg: 1H, 13C, 19F, 
35Cl etc. 
 The solvent used in the NMR spectroscopy should not contain hydrogen atoms. 
Hence we use solvents like carbon tetrachloride, Deuterated chloroform, Deuterated 
water, Deuterated dimethysulphoxide, Deuterated acetic acid, Deuterated triflouro 
acetic acid. 
 Any proton or nucleus with odd mass number spinning on its own axis by the 
application of an external magnetic field and radio frequency energy. When 
absorption of energy occurs and a NMR signal is recorded. 
 A combination of 60MHz radio frequency and a magnetic field strength of 
14,092gauss is applied for high resolution instruments, other combination is used. 
 1H NMR spectra were recorded on Bruker – NMR 400MHz using DMSO and 
chemical shifts were reported in parts per million and Tetra Methyl Silane is used as 
reference standard in NMR spectroscopy. 
 Chemical shift is the difference between the absorption position of the sample proton 
and absorption position of the reference compound. Chemical shift is measured in δ 
value and normal ranges from o - 10δ. 
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NMR SPECTRAL DATA 











Ar- H (9H) 
CH-Cl (1H) 
             2.5 
             1.2 
             2.9     
             2.2 
             7.4 
             3.3 
 
     D – E2   NH2 (2H) 
  CH3 (3H) 
  CH-CN (1H) 
  CH-N (1H) 
  Ar- H (9H) 
  OCH3 (3H) 
 
             3.4 
             2.5 
             2.5 
             3.5 
             7.3 
             3.7 
 
     D – E3 
 
  NH2(2H) 
  CH3 (3H) 
  CH-CN (1H) 
  CH-N (1H) 
  Ar- H (9H) 
  N(CH3)2 
 
             2.2 
             1.3 
             2.5 
             4.2 
             7.6 
             6.5 
    D – E4   NH2(2H) 
  CH3 (3H) 
  CH-CN (1H) 
  CH-N (1H) 
  Ar- H (10H) 
  CH =CH 
 
            2.7 
            1.2 
            2.4 
            3.9 
            7.4 
            2.1 
   D – E 5   NH2(2H) 
  CH3 (3H) 
  CH-CN (1H) 
  CH-N (1H) 
  Ar- H (10H) 
 
            2.5 
            1.3 
            2.7 
            2.5 
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13 1 2  1 1  1 0  9 8  7   6 5 4 3 2 1 0  p p m  











 0 . 6 1      
 
C u r re n t  D a t a  P a r a m e t e rs  
N A M E  F e b 1 1 - 2 0 1 4
E X P N O  5
P R O C N O  1
F2 -  Acquisition Parameters
D a t e _  2 0 1 4 0 2 1 1
T im e  2 1 . 4 9
I N S T R U M  s p e c t
P R O B H D  5  m m  P A B B O  B B -  
PULPROG zg30
T D  3 2 7 6 8
S O L V E N T  DMSO
N S  3 2
D S  2
S W H  10330.578 Hz
F ID R E S  0 . 3 1 5 2 6 4  H z
A Q  1 . 5 8 6 0 2 1 2  s e c
R G  2 0 3
D W  4 8 . 4 0 0  u s e c
D E  6 .5 0  u s e c
T E  3 0 0 . 0  K
D 1  1.00000000 sec
T D 0  1 
= = = = = = = =  C H A N N E L  f 1  = = = = = = = =
N U C 1  1 H
P 1  1 0 .6 5  u s e c
P L 1  0 . 0 0  d B
P L 1 W  2 3 . 5 3 6 3 7 5 0 5  W
S F O 1  500.1330885 MHz 
F 2  -  P r o c e s s i n g  p a ra m e t e r s 
S I  3 2 7 6 8
S F  500.1300000 MHz
W D W  E M
S S B  0
L B  0 . 3 0  H z
G B  0








































13 12  1 1  1 0  9 8  7 6 5 4 3 2 1 0  ppm  






3      
 
C urren t D ata Param eters 
N AM E  Fe b11- 2014
EXPN O  26
PR OCN O  1
F2 -  Acquisition Parameters
D ate_ 20140211
T im e 10.47
INST RU M sp ect
PR OBH D 5 m m  PA BB O B B-  
PULPROG zg30
T D 32768
SOL VENT  DMSO
N S  32
D S  2
SW H 10330.578 Hz
F ID RES  0.315264 H z
A Q  1.5860212 sec
R G  203
D W 48.400 u sec
D E  6.50 u sec
T E  299.2 K
D 1 1.00000000 sec
T D0 1 
= ==== === CH AN NEL  f1 === ==== =
N UC 1 1H
P1 10.65 u sec
PL 1 0.00 d B
PL 1W 23.53637505 W
SF O1 500.1330885 MHz 
F 2 -  Processing  p aram eters 
SI  3276 8
SF  500.1300036 MHz
W DW  EM
SSB  0
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13 1 2  1 1  1 0  9  8  7  6 5 4 3 2 1 0  p p m
   1.0




     3 . 0 0  
 
C u r re n t  D a t a  P a ra m e t e r s 
N A M E  F e b 1 1 - 2 0 1 4
E X P N O  7  
P R O C N O  1
F2 -  Acquisition Parameters
D a t e _  2 0 1 4 0 2 1 1
T im e 2 1 . 5 6  
I N S T R U M  s p e c t
P R O B H D  5  m m  P A B B O  B B -  
PULPROG zg30
T D  3 2 7 6 8  
S O L V E N T  DMSO
N S  3 2  
D S  2  
S W H  10330.578 Hz
F ID R E S  0 . 3 1 5 2 6 4  H z
A Q  1 . 5 8 6 0 2 1 2  s e c
R G  1 6 1  
D W  4 8 .4 0 0  u s e c
D E  6 . 5 0  u s e c
T E  3 0 0 . 1  K  
D 1  1.00000000 sec
T D 0  1   
= = = = = = = =  C H A N N E L  f 1  = = = = = = = =
N U C 1  1 H  
P 1  1 0 .6 5  u s e c
P L 1  0 . 0 0  d B  
P L 1 W  2 3 . 5 3 6 3 7 5 0 5  W
S F O 1  500.1330885 MHz 
F 2  -  P r o c e s s i n g  p a ra m e t e r s  
S I  3 2 7 6 8  
S F  500.1300039 MHz
W D W  E M  
S S B  0  
L B  0 . 3 0  H z  
G B  0  








































13 12  1 1  1 0  9 8  7 6 5 4 3 2 1 0  p p m  













  1 9 . 9 1    
 
C ur re n t D a ta  P a r a m e te rs  
N AM E  Fe b 1 1 - 2 0 1 4
E X P N O  2
P R O CN O  1
F2 -  Acquisition Parameters
D a te _  2 0 1 4 0 2 1 1
T im e  2 1 . 3 9
I NS T RU M  s p e c t
P R O BH D  5  m m  P A BB O  B B-  
PULPROG zg30
T D  3 2 7 6 8
S O L V E NT  DMSO
N S  3 2  
D S  2  
S W H  10330.578 Hz
F ID RE S  0 . 3 1 5 2 6 4  H z
A Q  1 . 5 8 6 0 2 1 2  s e c
R G  1 8 1
D W  4 8 . 4 0 0  u s e c
D E  6 . 5 0  u s e c
T E  2 9 9 . 9  K
D 1  1.00000000 sec
T D0  1   
= ==== === CH AN NE L  f1  === ==== =
N UC 1  1 H
P 1  1 0 .6 5  us e c
P L 1  0 . 0 0  d B
P L 1 W  2 3 . 5 3 6 3 7 5 0 5  W
S F O 1  500.1330885 MHz 
F 2  -  P r oc e s s i ng  p a ra m e te r s  
S I  3 2 7 6 8 
S F  500.1300000 MHz
W DW  E M
S S B  0  
L B  0 . 3 0  H z
G B  0  
P C  1 . 0 0  
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TD0 1  





SFO1 500.1330885 MHz 
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 2 . 0 0   2.6
6    
 
C u r re n t  D a t a  P a r a m e t e rs  
N A M E  F e b 1 1 - 2 0 1 4
E X P N O  1 2  
P R O C N O  1
F2 -  Acquisition Parameters
D a t e _  2 0 1 4 0 2 1 1
T im e  2 2 . 1 3  
I N S T R U M  s p e c t
P R O B H D  5  m m  P A B B O  B B -  
PULPROG zg30
T D  3 2 7 6 8  
S O L V E N T  DMSO
N S  3 2  
D S  2  
S W H  10330.578 Hz
F ID R E S  0 . 3 1 5 2 6 4  H z
A Q  1 . 5 8 6 0 2 1 2  s e c
R G  2 0 3  
D W  4 8 . 4 0 0  u s e c
D E  6 . 5 0  u s e c
T E  3 0 0 . 1  K  
D 1  1.00000000 sec
T D 0  1   
= = = = = = = =  C H A N N E L  f 1  = = = = = = = =
N U C 1  1 H  
P 1  1 0 .6 5  u s e c
P L 1  0 . 0 0  d B
P L 1 W  2 3 . 5 3 6 3 7 5 0 5  W
S F O 1  500.1330885 MHz 
F 2  -  P r o c e s s i n g  p a r a m e t e r s  
S I  3 2 7 6 8  
S F  500.1300000 MHz
W D W  E M  
S S B  0  
L B  0 . 3 0  H z  
G B  0  
P C  1 . 0 0  
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13 12  1 1  1 0  9  8  7  6 5 4 3 2 1 0  p p m






3      
C ur re n t D a ta  P a r a m e te rs  
N A M E  Fe b1 1 - 2 0 1 4  
E X P N O  2 6  
P R O C N O  1  
F2 -  Acquisition Parameters
D a te _  2 0 1 4 0 2 1 1  
T im e  1 0 . 4 7  
I N S T R U M  s p e c t 
P R O B H D  5  m m  P A B B O  B B -  
PULPROG zg30 
T D  32768 
S O L V E N T  DMSO 
N S  32  
D S  2  
S W H  10330.578 Hz  
F ID R E S  0 . 3 1 5 2 6 4  H z 
A Q  1 . 5 8 6 0 2 1 2  s e c  
R G  203 
D W  4 8 . 4 0 0  u s e c  
D E  6 . 5 0  u s e c  
T E  2 9 9 .2  K  
D 1  1.00000000 sec
T D 0  1   
= = = = = = = =  C H A N N E L  f1  = = = = = = = =
N U C 1  1H 
P 1  1 0 . 6 5  u s ec  
P L 1  0 . 0 0  d B  
P L 1 W  2 3 . 5 3 6 3 7 5 0 5  W
S F O 1  500.1330885 MHz 
F 2  -  P r oc e s s i ng  p a ra m e te r s  
S I  3 2 7 6 8 
S F  500.1300036 MHz
W D W  E M  
S S B  0  
L B  0 . 3 0  H z 
G B  0  








































13 12  11  10  9  8  7  6 5 4 3 2 1 0 ppm
   1.0




     3 . 0 0 
C urrent D ata Parameters 
N AM E Feb 11- 2014
EXPN O 7 
PR OCN O 1 
F2 -  Acquisition Parameters
D ate_ 20140211 
T im e 21.56 
INST RU M spect 
PR OBH D 5 mm PAB BO B B-  
PULPROG zg30 
T D 32768 
SOLVENT  DMSO 
N S 32 
D S 2 
SW H 10330.578 Hz 
F ID RES 0.315264 Hz 
A Q 1.5860212 sec 
R G 161 
D W 48 .400 usec 
D E 6.50 usec 
T E 300.1 K 
D 1 1.00000000 sec
T D0 1  
= === ====  C HAN NEL  f1 == ==== ==
N UC 1 1H 
P1 10.6 5 usec 
PL1 0.00 dB 
PL1W 23.53637505 W
SFO1 500.1330885 MHz 
F 2 -  Processing  p arameters 
SI 3 2768 
SF  500.1300039 MHz
W DW  EM  
SSB  0  
L B 0.30 Hz 
GB  0  
PC  1.00 
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  1 9 . 9 1     
 
C ur re n t D a ta  P a r a m e te rs  
N A M E  Fe b 1 1 - 2 0 1 4
E X P N O  2  
P R O C N O  1
F2 -  Acquisition Parameters
D a te _  2 0 1 4 0 2 1 1
T im e  2 1 . 3 9
I N S T R U M  s p e c t
P R O B H D  5  m m  P A B B O  B B -  
PULPROG zg30
T D  3 2 7 6 8  
S O L V E N T  DMSO
N S  3 2  
D S  2  
S W H  10330.578 Hz
F ID R E S  0 . 3 1 5 2 6 4  H z
A Q  1 . 5 8 6 0 2 1 2  s e c
R G  1 8 1  
D W  4 8 . 4 0 0  u s e c
D E  6 . 5 0  u s e c
T E  2 9 9 . 9  K
D 1  1.00000000 sec
T D 0  1   
= = == = = = =  C H A N N E L  f1  = == == = = =
N U C 1  1 H  
P 1  1 0 .6 5  us e c
P L 1  0 . 0 0  d B
P L 1 W  2 3 . 5 3 6 3 7 5 0 5  W
S F O 1  500.1330885 MHz 
F 2  -  P r oc e s s i ng  p a ra m e te r s  
S I  3 2 7 6 8 
S F  500.1300000 MHz
W D W  E M  
S S B  0  
L B  0 . 3 0  H z 
G B  0  
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 2 . 0 0  2.6
6    
 
C ur ren t D a ta  P ar am ete rs  
N AM E  F e b11 - 2014
E X P N O  1 2  
P R O CN O  1
F2 -  Acquisition Parameters
D ate_  20140 211
T im e  22 . 13
INS T RU M  s p ec t
P R O BH D  5  m m  P A BB O  B B-  
PULPROG zg30
T D  32768
S O L V E NT  DMSO
N S  32  
D S  2  
S W H  10330.578 Hz
F ID RE S  0 .315 264  H z
A Q  1 .586 0212  se c
R G  20 3  
D W  48 . 400  u sec
D E  6 .5 0  u s ec
T E  300 .1  K
D 1  1.00000000 sec
T D0  1   
= ==== === CH AN NE L  f1  === ==== =
N UC 1  1 H  
P 1  10 .65  usec
P L 1  0 .0 0  d B
P L 1W  23 . 53637 505  W
S F O 1  500.1330885 MHz 
F 2  -  P r oce ss ing  p aram ete r s  
S I  3276 8 
S F  500.1300000 MHz
W DW  E M  
S S B  0  
L B  0 . 30  H z 
G B  0  
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8. PHARMACOLOGICAL EVALUATION 
8.1 INVITRO ANTIOXIDANT ACTIVITY54 
DPPH method 
 The free radical scavenging activity of the synthesized compound is evaluated by 
assessing their ability to reduce the colour of DPPH in chloroform. DPPH stable free radical 
method is an easy, rapid sensitive way to survey the antioxidant activity of specific 
compound. 
Principle 
A simple method has been developed to determine the antioxidant activity of 
synthesized compounds utilizes the stable 2, 2-diphenyl -1-picrylhydrazyl (DPPH) radical. 
The odd electron in the DPPH free radical gives a strong absorption maximum at 517nm and 
purple in colour. The colour turns from purple to yellow as the molar absorptivity of the 
DPPH radical becomes paired with hydrogen from a free radical scavenging antioxidant to 
form the reduce DPPH-H. The resulting decolourization is stiochiometric with respect to 
number of electron captured.   




 Shimadzu UV Visible spectrometer, Model 1800. 
Reagent 
0.1Mm Diphenyl Picryl Hydrazyl Radical in chloroform. 
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Procedure 
A stock solution of 1mg/ml concentration of synthesized compound was prepared. To 
the 1ml of various concentrations of test samples, 4ml of DPPH solution was added. Control 
was prepared without sample in an identical manner. DPPH was replaced by chloroform in 
case of blank. The reaction was allowed to be completed in the dark for about 30min. Then 
the absorbance was measured at 517nm. The percentage scavenging was calculated using the 
formula [(Control-Test)/Control]/100.  
ANTIOXIDANT ACTIVITY OF SYNTHESIZED COMPOUNDS 
Table No: 11 
COMPOUND 
CODE 
ABSORBANCE OF DIFFERENT 
CONCENTRATION 
50µg/ml 100µg/ml 150µg/ml 
D – E1 0.910±0.0095 0.776±0.0049 0.585±0.0083 
D – E2 0.947±0.0066 0.815±0.0052 0.560±0.0092 
D – E3 0.747±0.0069 0.533±0.0052 0.355±0.0050 
D – E4 0.950±0.0084 0.805±0.0080 0.513±0.0053 
D – E5 0.870±0.0037 0.759±0.0025 0.467±0.0049 
D – E6 0.808±0.0083 0.744±0.0078 0.402±0.0083 
D – E7 0.791±0.0063 0.603±0.0087 0.397±0.0060 
D – E8 0.782±0.0038 0.586±0.0036 0.383±0.0084 
D – E9 0.761±0.0049 0.568±0.0073 0.364±0.0043 
D – E10 0.977±0.0069 0.758±0.0060 0.534±0.0034 
Standard 1.288±0.0221 0.829±0.0094 0.516±0.0043 
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ANTIOXIDANT ACTIVITY OF COMPOUNDS D – E1 TO D – E5 
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8.2 INVITRO ANTICANCER ACTIVITY54, 55 
Cell line 
The human osteosarcoma cell line (MG 63) was obtained from National Centre for Cell 
Science (NCCS), Pune and grown in Eagles Minimum Essential Medium containing 10% fetal bovine 
serum (FBS). The cells were maintained at 370C, 5% CO2, 95% air and 100% relative humidity. 
Maintenance cultures were passaged weekly, and the culture medium was changed twice a week. 
Cell treatment procedure 
The monolayer cells were detached with trypsin-ethylenediaminetetraacetic acid (EDTA) to 
make single cell suspensions and viable cells were counted using a hemocytometer and diluted with 
medium containing 5% FBS to give final density of 1x105 cells/ml. One hundred microlitres per well 
of cell suspension were seeded into 96-well plates at plating density of 10,000 cells/well and 
incubated to allow for cell attachment at 370C, 5% CO2, 95% air and 100% relative humidity. After 24 
h the cells were treated with serial concentrations of the test samples. They were initially dissolved in 
neat dimethylsulfoxide (DMSO) and an aliquot of the sample solution was diluted to twice the desired 
final maximum test concentration with serum free medium. Additional four serial dilutions were made 
to provide a total of five sample concentrations. Aliquots of 100 µl of these different sample dilutions 
were added to the appropriate wells already containing 100 µl of medium, resulting in the required 
final sample concentrations. Following sample addition, the plates were incubated for an additional 48 
h at 370C, 5% CO2, 95% air and 100% relative humidity. The medium containing without samples 
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MTT assay 
 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) is a yellow water soluble 
tetrazolium salt. A mitochondrial enzyme in living cells, succinate-dehydrogenase, cleaves the 
tetrazolium ring, converting the MTT to an insoluble purple formazan. Therefore,the amount of 
formazan produced is directly proportional to the number of viable cells. 
After 48 h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) was 
added to each well and incubated at 370C for 4h. The medium with MTT was then flicked off and the 
formed formazan crystals were solubilized in 100µl of DMSO and then measured the absorbance at 
570 nm using micro plate reader. The percentage cell viability was then calculated with respect to 
control as follows 
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INVITRO ANTICANCFR ACTIVITY (COMPOUND D – E3) 
                 Control                                                          0.1µgM 
             
                        1.0µM                                                                  10µM 
                 
                            50µM                                                                  100µM 
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    ℅CELL 
VIABILITY 
     D – E2                0.1 
               1 
               10 
               50 
              100 
 
          101 
          100 
            95 
            92 
            80 
     D – E3                0.1 
               1 
               10 
               50 
              100 
 
             94 
             92 
             88 
             69 
             54 
    D – E4                0.1 
               1 
               10 
               50 
              100 
 
            100 
             97 
             94 
             73 
             70 
   D – E7                0.1 
               1 
               10 
               50 
              100 
 
           102 
           100 
             96 
             91 
             86 
 
    D – E8                0.1 
               1 
               10 
               50 
              100 
 
           91 
           89 
           85 
           67 
           57 
    D – E9                0.1 
               1 
               10 
               50 
              100 
 
          101 
           97 
           90 
           85 
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ANTICANCER ACTIVITY OF COMPOUNDS D-E2, D-E3, D-E4 
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10.3. ANTIBACTERIAL ACTIVITY6, 27 
The microbial assay is based upon a comparison of the inhibition of growth of 
microorganism. 
Antimicrobial activity of various synthesized compounds was studied by the presence 
of zone of inhibition. 
 The antibacterial activities of the synthesized compounds were studied by disc 
diffusion method. 
 All the compounds were used in the concentration of 150μg/ml, 300μg/ml using a 
solvent DMSO. 
Details of micro organisms 
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PREPARATION OF MULLER HINTON AGAR 
 
Composition 
Beef extract    - 10 g 
Casein acid hydrosylate   - 17.5 g 
Starch     - 1.5 g 
Agar        - 20 g 
Water     - 1000 ml 
 
Procedure 
The constituents are dissolved in distilled water and the pH was adjusted to 7.2, 
then the medium was sterilized in an autoclave at 121◦C for 15 minutes and it was 
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ANTIBACTERIAL ACTIVITY (By disc diffusion method) 
Muller-Hinton agar medium was prepared and transferred into sterile petriplates 
aseptically with the thickness of 5 – 6mm.The plates were allowed to dry at room temperature 
and were inverted to prevent condensate falling on the agar surface. Uniform thickness of the 
medium was obtained by placing the plates on leveled surface. 
 
Standardized bacterial inoculums were applied to the plates and spread uniformly 
over the surface of the medium by using a sterile non – absorbent cotton swap and finally the 
swap was passed around the edge of the medium. The inoculated plates were closed with the 
lid and allow drying at room temperature. 
 
The sample impregnated discs were placed on the inoculated agar medium. All 
petriplates were incubated at 37◦C for 24 hours. After incubation, diameter of zone of 
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ZONE OF INHIBITION IN MM 
E.COLI  STAPH.EPIDERMIDIS  STREP.PYOGENES 
150µg/ml  300µg/ml  150µg/ml 300µg/ml  150µg/ml  300µg/ml
D – E1  4  11  R  5  12  12 
D – E2  5  8  9  12  4  7 
D – E3  12  15  7  15  11  14 
D – E4  9  12  10  14  8  16 
D – E5  8  7  12  14  R  6 
D – E6  9  10  R  2  9  11 
D – E7  6  6  4  7  6  9 
D – E8  7  9  8  11  8  14 
D – E9  9  12  12  16  7  13 
D – E10  8  10  6  9  4  10 
CONTROL  R  R  R  R  R  R 
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                           ANTIBACTERIAL ACTIVITY AGAINST E.COLI       
                      
                          ANTIBACTERIAL ACTIVITY AGAINST STAPH.EPIDERMIS 
                
      ANTIBACTERIAL ACTIVITY AGAINST STREP.PYOGENES             
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8.4. ANTIFUNGAL ACTIVITY9, 27 
The microbial assay is based upon a comparison of the inhibition of growth of 
microorganism. 
Antifungal activity of various synthesized compounds was studied by the presence of 
zone of inhibition. 
 The antifungal activitiy of the synthesized compounds were studied by disc diffusion 
method. 
 All the compounds were used in the concentration of 150μg/ml, 300μg/ml using a 
solvent DMSO. 
Details of micro organism 
Table No: 15 
S. NO ORGANISM 
1 Candida albicans 










Chapter VIII                                                         Pharmacological Evaluation  
 
Department of Pharmaceutical Chemistry  Page 136 
 




Potato    - 200g 
Dextrose   - 20g  
Agar     - 20g 
Water   - 1000ml 
 
Procedure 
Scrub but do not peel the potatoes and cut into 12mm cubes. Boil 200g potato in 1litre 
of water for 60 minutes. Squeeze as much of the pulp as possible through a fine sieve. Add 
agar and boil till dissolved. Add dextrose and make up to 1litre. Dispense in requiredamounts 
taking care to keep solids in suspension. Autoclave at 115°C and pour approximately 20ml 
amounts into petri dishes.  
 
ANTIFUNGAL ACTIVITY (By disc diffusion method) 
The plates were inoculated by dipping a sterile swab into inoculums. The inoculation 
was dried at room temperature in aseptic condition. Ditch the bore in plate, to this bore add 
prepared antibacterial solution. These plates were placed in an incubator at 22°C within a few 
minutes of preparation. After 7 days of incubation the diameter of zone of inhibition was 
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ANTIFUNGAL ACTIVITY AGAINST FUNGI 
Table No: 16 
COMPOUND
CODE 
ZONE OF INHIBITION IN MM 
CANDIDA ALBICANS  ASPERGILLUSPARACITICUS 
150µg/ml  300µg/ml  150µg/ml  300µg/ml 
D – E1 
  17  21  14  15 
D – E2 
  16  19  12  16 
D – E3 
  14  21  10  14 
D – E4 
  17  18  11  17 
D – E5 
  10  13  14  13 
D –E6 
  14  19  9  14 
D – E7 
  18  16  13  16 
D – E8 
  15  19  11  18 
D – E9 
  14  19  15  23 
D – E10 
  12  17  16  18 
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9. RESULT AND DISCUSSION 
 In this present study, the molecular designing of the compounds were carried out by 
using different software. 
 The lipinkis rule of five was calculated by chemdoodle software and results were 
shown in Table No:1 
 The Molecular formula, Molecular weight and IUPAC name were predicted and 
shown in Table No: 2 & 3. 
 The compounds were synthesized by “Leuckart reaction” which shows good 
percentage yield, melting point and solubility of the compounds were determined and 
shown in Table No: 4 & 6. 
 The compounds are monitored by TLC and Rf value were calculated and shown in 
Table No:7 
 Elemental composition were found and calculated in percentage and results obtained 
were shown in Table No: 5 
 The compounds were confirmed by spectral analytical data. 
 The results for IR spectra are shown in Table No: 8 
 The results for NMR spectra are shown in Table No: 9 
 The results for MASS spectra are shown in Table No: 10 
 All the ten synthesized compounds were screened for their antioxidant, anticancer, 
antibacterial, antifungal activity. 
 The antioxidant activity was performed by DPPH method and results obtained were 
showed in Table No: 11 
 The anticancer activity (osteosarcoma) was performed by MTT assay method and 
results obtained were shown in Table No:12 
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 The antibacterial activity was performed against E. coli, Staphylococcus epidermis, 
Streptococcus pyogenes organism were shown in Table No:13 
 The zone of inhibition was performed by disc diffusion method. The results were 
measured in millimeter  and shown in Table No:14 
 The graphical representation of all the ten compounds were shown and compared with 
standard drug (Ofloxacin). 
 The antifungal activity was performed against Candida albicans and Aspergillus 
parasiticus were shown in Table No:15 
 The zone of inhibition was performed by disc diffusion method. The results were 
measured in millimeter  and shown in Table No:16 
 The graphical representation of all the ten compounds were shown and compared with 
standard drug (Fluconazole). 
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SUMMARY AND CONCLUSION 
 
 Preliminary screening of the 1-substituted tetrahydropyrimidine derivatives was done 
by using molinspiration, chemdoodle and chemsketch software. 
 The present study describes the synthesis of 1-substituted tetrahydropyrimidine 
derivatives by Leuckart reaction. This methodology offers the spirited advantages 
having lesser time reaction and yield higher percentage of products. 
 Melting point was found for the synthesized compound and purity of the synthesized 
compound was analyzed by TLC. 
 The structures of the synthesized compounds were elucidated by IR, NMR and Mass 
spectroscopy. 
 The synthesized compounds were screened for anti oxidant, anticancer, antibacterial, 
antifungal activity. 
 The in-vitro anti oxidant property for all the compounds showed positive results. 
The compounds D – E2, D – E3, D – E4, D – E7, D – E8, D – E9 showed more potent 
activity. These six compounds were selected and evaluated for anticancer activity. 
The results obtained showed that synthesized compounds D – E3, D – E8, showed 
anticancer activity against cancer cells.  
 It proves the suitable structural modification will have to be carried to get novel 
compound having potent anticancer activity with least effect on normal cells. 
 The antimicrobial activities of synthesized compounds were to obtained zone of 
inhibition by disc diffusion method. 
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 P-dimethylamino benzaldehyde and cinnamaldehyde based tetrahydropyrimidine 
derivatives were react with acetophenone and benzophenone which gives D – E3,            
D – E4 and D – E8, D – E9 respectively. These four compounds exibit best 
antibacterial activity as compared to standard drug (Ofloxacin). 
 Among the synthesized compounds were found to be good antifungal activity as 
compared to standard drug (Flucconazole). 
 Furthermore biological activities such as anticonvulsant, anti-inflammatory, 




            
 
           REFERENCE 
  
Chapter XI                                                                                       References   
 
Department of Pharmaceutical Chemistry   
 
11. REFERENCES 
1. Ilango .K and valentine.P, Text book of MC, vol-2 
2. Surendra nath pandeya,Text book of MC,3rd edition 2003, vol-3 
3. Agarwal .O.P, Organic chemistry, Reaction and Reagents, 2006,803. 
4. Bansal. R.K, Herocylic chemistry, 3rd edition, 2001, 453-454. 
5. Amir .M, Javed .S.A and Kumar .H, Indian Journal of Pharmaceutical Science, 2007, 
69(3), 337-343. 
6. Padmashri .B, Vaidya .V.P and Vijayakumar .M.L,Indian Journal of Heterocyclic. 
Chem, 2002, 12, 89-94. 
7. Shishoo .C.J, Pathak .U.S, Jain. K.D,Devani. I.T,Chabria .M.T, Chem Inform, 1994, 
25(38), 436-440. 
8. Mishra. A and Singh .D.V,Indian Journal Heterocyclic Chemistry, 2004, 14, 43-46. 
9. Fathalla .O.A, Zeid I.F, Haiba M.E, Soliman A.M, Abd- Elmoez, Serwy.W.S, World 
Chem, S2009, 4 (2),127. 
10. Padmashale .B, Vaidya. V. P, Vijaya Kumar M. L,Indian J. Hetero. Chem.2002,12,89 
11. Lee.H. W, Kim B.Y,Euro. J, Med. Chem, 2005, 4, 662. 
12. Desenko S. M, Lipsum V. V, Gorbenko. N. I, Jour. Pharm. Chem, 1995, 29, 265. 
13. Rahaman. S.A,RajendraPasad .Y, Phani Kumar, Bharath Kumar, Saudi 
Pharmaceutical Journal, 2009, 17(3), 259. 
14. Gurudeep Chatwal, Sham Anand , Instrumental methods of chemical analysis. 
15. Vishwanadhan .C.L, Joshi .A.A and Sachin .S.N, Bioorg. Med. Chem. Lett, 2005, 15, 
16. Bruni .O, Brullo .C, Ranise. A,Schenone . S, Bondavalls .S, Barvocelli.E, Ballabeni 
.V, Chivarani.M, Tognolini.M and Jmpicciatore. M, Bioorg.Med. Chem. Lett, 
2001,11,1397. 
Chapter XI                                                                                       References   
 
Department of Pharmaceutical Chemistry   
 
17. Sheriff .A.F.R, Fahmy Hesham.T.Y and Saudi Manal .N.S, Scientia Pharmaceutica, 
2003, 71, 57. 
18. Pandeya. S, Suryawanshi .S.N, Suman.G and Srivastavam.V.M.L, Eur. J. Med. Chem, 
2004, 39,969. 
19. Joubran. L, Jackson. W. R, Compi. E. M, Robinson. A. J, Wells. B. A, Godfreay. P. 
D, Callaway .J. K. and Jaraott .B, Austrian J. Chem, 2003, 56,597.  
20. Burger. A, in Burger’s Medicinal Chemistry and Drug Discovery, John- Wiley 
publications Inc. 5th Edition 1995. 
21. Regnier G.L, Canevar. R.J, Douarec .L, Halstop .S, Jour. Med. Chem.19721, 295. 
22. Suguira A.F,  Schmid.M.M,  Brown. F.G,Cancer Chemother.  Rep. Part 2, 1973, 231. 
23.  Srinivas .K.V.N.S, Das .S,Synthesis, 2004, 13, 2091.  
24. Sun .Q, Wang .Z, Synthesis, 2004, 1047.26.National Cancer Institute at the National 
Institutes of health, 2008, 100(11)773-783. 
25.  Jie Ma and David Waxman.J, Mol cancer Ther. 2008 7(12), 3670-3684.  
26.   Practical Medical Microbiology Mackie and McCartney 114th Edition.  
27.   Text book of microbiology 8th Edition Ananthanarayan and Paniker. 
28.  Text book of microbiology 4th Edition Dir.Prof.C.P.Bavesia. 
29. RobertM.Silverstein, G.Clayton Basster, Spectrophotometric, Identification of organic 
compounds 2nd Edition, 72-135. 
30. Sharma B.K, Instrumental methods of chemical Analysis, 24th Edit-2005.  
31. Tripathi. K.D, Essential of medical pharmacology, 5th Edition, Medical Publishers.  
32. .Jaime, Merchan .R, Barden Chan Sujata Kale, Lowell E.Schnipper, Vikas P. 
Sukhatme, Journal of National cancer Institute Vol-95 2003,5. 
33.   Sankara Adithya .V.S.P.K, Naresh kumar .L, cancer activity- International Journal of 
Pharma sciences Vol-3, 2013, 185-188. 
Chapter XI                                                                                       References   
 
Department of Pharmaceutical Chemistry   
 
34. Pranay Dogra, Study of Antibacterial and Anticancer Activity of Selected Trifoliate 
Plants. Biofrontiers2009, 1(2): 4-8.  
35. Skehan. P, Storeng.R, Scudiero.D,Monks.A, McMahon. J, Vistica.D etal.New 
Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. Journal National 
Cancer Institute 1990, 82(13), 1107-1112. 
36. Masters .R.W, Animal cell culture, Cytotoxicity and viability assays.3rd edition 2000,  
202 -203. 
37. Wilson.A.P. Cytotoxicity and Viability Assays in Animal Cell Culture,                        
APractical Approach. 3rd ed, Oxford University Press,Oxford Vol. 1; 2000.  
38. Masters .R.W, Animal cell culture,Cytotoxicity and viability assays. 3rd ed. 2000, 
207. 
39. ArunBahl, Bahl .B.S,Text book of Advanced Organic Chemistry 
40. Mahendra .R, Text book of Quantum Chemistry. 
41. Noor shahina begum, journal of chemical science vol-124, 2012, 847-855. 
42. Andrews.B, and Mansur Ahmed, Journal of chemical and pharmaceutical research, 
2012,4 (8), 3920 – 3923. 
43.  Zulbiye Onal, BehzatAltural, Turk journal of chemistry, 1999, 401-405 . 
44.  Mossad S. Mohamed, Amira Ibrahim Syed, 2010, 15, 1882-1890. 
45. Ahmed .M.M, Nabil .A, Somia .O,  J. Chem  vol-3, 2008, 223 -232. 
46. Wagh ware .G.S, Junne .S.B, Chemical Science Transactions , 2013, 1-4. 
47.  AzzaTaherTaher and Sahar Mohmed Abou Seri, 2012, 17, 1868-1886. 
48. Sharma .Y.R, Text book of elementary organic spectroscopy. 
49. Theopphill Eicher and Siegfried Haupman , heterocyclic chemistry 2’ nd edition. 
50. Rekka .E, Text book of drug design and development. 
51. Vadim kotlyar , Abraham, Huge .E, J,org.chem.1997, 62,7512-7515. 
Chapter XI                                                                                       References   
 
Department of Pharmaceutical Chemistry   
 
52.  Anjana Bhatewara, srivas Rao jetti, Pradeep Paliwal, Archives of Applied Science 
Research. 2012, 1274-1278. 
53. Siels, Helmet(1997).,Experimental Physioogy 82(2): 291-5 
54. Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. Journal of Immunological 
Methods, 65, 55-63. 
55. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., 
Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, 
J., Boyd, 1991. Feasibility of high flux anticancer drug screen using a diverse panel of 
cultured human tumour cell lines. Journal of the National Cancer Institute, 83, 757-
766. 
 
 
 
 
